BlackRock
BLTE icon

BlackRock’s Belite Bio BLTE Stock Holding History

BlackRock’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.87K Buy
+11
New +$1.78K ﹤0.01% 5669
2024
Q1 		– Sell
-1,805
Closed -$82.6K – 5287
2023
Q4 		$82.6K Buy
+1,805
New +$69.4K ﹤0.01% 4862
2023
Q3 		– Sell
-966
Closed -$13.8K – 5454
2023
Q2 		$13.8K Sell
966
-91
-9% -$2.07K ﹤0.01% 5233
2023
Q1 		$31.6K Buy
1,057
+186
+21% +$5.65K ﹤0.01% 5188
2022
Q4 		$26.3K Buy
+871
New +$25.7K ﹤0.01% 5344

Other funds holding BLTE

Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
NM
NWI Management New York $2.67B AUM 61.94% 1-Year Est. Return

BlackRock's BLTE Position: Q3 2026 in Review

BlackRock opened a new position in Belite Bio (BLTE) in Q3 2026: 11 shares worth $1.87K. The stake represents ﹤0.01% of the portfolio and ranks #5669 among its holdings. This is a return to the name: BlackRock previously reported a position in BLTE as recently as Q4 2023.

BlackRock first reported a position in BLTE in Q4 2022 and has held it in 5 quarters since. The position peaked at $82.6K in Q4 2023. 54 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • BlackRock held 11 shares of Belite Bio worth $1.87K as of Q3 2026.
  • Belite Bio was a new BlackRock position in Q3 2026.
  • Belite Bio made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #5669 holding.
  • BlackRock first reported a position in Belite Bio in Q4 2022 and has held it in 5 quarters since.
  • BlackRock's Belite Bio position peaked at $82.6K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.